GNRO — Geneuro SA Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
Brief: Geneuro Reports Q1 Cash Position Of 13.3 Million Euros
Brief: Geneuro FY Operating Loss Widens To 8.1 Million Euros
Brief: Geneuro’S ANGEL-MS Phase 2b Extension Study Confirms Neuroprotective Effects Of Temelimab In MS
Brief: Geneuro Cash Position 16.5 Million Euros At 31 December
Brief: GeNeuro Announces Positive Results From Temelimab Phase 1 High-Dose Clinical Trial
Brief: Geneuro Seals 7.5 Million Euro Financing Agreement With Institut Mérieux Subsidiary
Brief: Geneuro Cash Position Down At 12.9 Million Euros At 30 September
Brief: Geneuro Confirms Potential Of Novel PHERV-K Antibodies For ALS
Brief: GeNeuro Presents Phase 2B Data Demonstrating Neuroprotective Effect Of GNbAC1 In Multiple Sclerosis Patients
Brief: Geneuro to present 12 Month data on anti-Neurodegeneration effects of Gnbac1 From Change-MS Phase 2B Study
Brief: Geneuro Announces Positive 6-Month Phase IIA Data For GNBAC1
Brief: Geneuro H1 Net Loss Narrows To 2.3 Million Euros
Brief: GeNeuro Regains Worldwide Rights Ex US And Japan To GNbAC1 In Multiple Sclerosis From Servier
Brief: Geneuro Q2 Operating Income Of EUR 4.34 Million
Brief: Geneuro: Preclinical Models Confirm Involvement Of pHERV-W-Env In Human Type 1 Diabetes Pathogenesis
Brief: Geneuro To Present New Data At American Diabetes Association’s 78th Scientific Session
Brief: GeNeuro Q1 2018 Operating Revenues Up at 2.9 Million Euros
Brief: Geneuro FY Net Loss For The Period Narrows To 5.8 Million Euros
Brief: Geneuro Receives Orphan Drug Designation From The Us FDA For Gnbac1 In Chronic Inflammatory Demyelinating Polyneuropathy (Cidp)